Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
AI drugs researcher QuantumPharm makes market debut on long road to profit
The newly floated biotech can boast big-name backers and counts more than a dozen biopharma heavyweights among its customers, but it is still awash with red ink Key Takeaways: QuantumPharm’s…
ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…